Literature DB >> 8711760

Immunochemical characterization of type A botulinum neurotoxin in its purified and complexed forms.

B R Singh1, T Lopes, M A Silvia.   

Abstract

Immunochemical reactivities of type A botulinum neurotoxin to polyclonal antibodies raised against the neurotoxin complex toxoid have been investigated using enzyme-linked immunosorbent assay (ELISA) and with a fiberoptic immunosensor. The complex contains a group of complexing proteins in addition to the neurotoxin itself. Neurotoxin specific immunoglobulin G (IgG), purified from the IgG raised against the complex using an affinity column, showed a two-fold increase in reactivity with purified neurotoxin compared to the neurotoxin in the complex. Antibodies against the whole complex reacted approximately five times better with the complex than with the neurotoxin, suggesting that the detection of the neurotoxin complex may be more sensitive. Considering the fact that the amount of the complexing proteins and neurotoxin appears to be in a 4:1 ratio, a five-fold higher reactivity could suggest a 25-fold higher detectability of the neurotoxin in the complex. ELISA binding curves of complexing proteins and purified neurotoxin with antibodies raised against the whole complex indicated the complexing proteins to have significantly higher antigenicity. Furthermore, IgG fraction with or without the neurotoxin specific antibodies reacted almost equally to the neurotoxin complex, again suggesting higher immunogenicity of the complexing proteins. Increased binding of the complexing proteins versus the purified neurotoxin to antibodies against the complex and thus immunogenicity was also observed in the binding curves generated using a fiberoptic immunosensor.

Mesh:

Substances:

Year:  1996        PMID: 8711760     DOI: 10.1016/0041-0101(95)00113-1

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  3 in total

1.  Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.

Authors:  Anne-Marie Bryant; Shuowei Cai; Bal Ram Singh
Journal:  Toxicon       Date:  2013-06-28       Impact factor: 3.033

2.  A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.

Authors:  Joohi Jimenez-Shahed
Journal:  Neuropsychiatr Dis Treat       Date:  2011-12-23       Impact factor: 2.570

3.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.